Oxiglutatione
A form of glutathione (the reduced tripeptide) used topically in eye drops to protect the corneal epithelium during ocular procedures and to treat conditions associated with oxidative stress in the eye. It acts as an antioxidant, neutralizing reactive oxygen species that can damage eye tissue.
Masse moléculaire
612,6000 g/mol
LogP
-9,10
TPSA
368,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Structure 2D
Cite this structure
Embed this structure
SMILES
N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
InChI
InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
Molecular Formula
C20H32N6O12S2
HBD / HBA
10 / 16
Liaisons Rotatives
21
Atomes Lourds
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A form of glutathione (the reduced tripeptide) used topically in eye drops to protect the corneal epithelium during ocular procedures and to treat conditions associated with oxidative stress in the eye. It acts as an antioxidant, neutralizing reactive oxygen species that can damage eye tissue.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Oxiglutatione is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1372. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65359. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="oxiglutatione"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/oxiglutatione/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/oxiglutatione/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/oxiglutatione/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="oxiglutatione"></drugfyi-drug>